source
- Innovent Biologics reports Phase 3 success for stomach cancer ADC, now under priority review in ChinaInnovent Biologics announced that its antibody‑drug conjugate (ADC) candidate has met the primary endpoint in a Phase 3 trial for advanced stomach cancer. The positive outcome has placed the produ…
- Fulcrum Therapeutics cuts workforce, retaining only nine employees as layoffs hit 48 staffFulcrum Therapeutics announced a dramatic reduction in its staff, letting go of 48 of its 57 full‑time employees. The move leaves the company with just nine remaining workers, effectively turning i…